Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure
News Aug 03, 2007
Quark Pharmaceuticals, Inc. has announced the presentation of positive results from preclinical efficacy studies for its systemically-administered, siRNA compound, AKIi-5, in acute renal failure (ARF).
In the study, rats treated with a single bolus injection of rat AKIi-5, Quark's siRNA compound targeting the p53 gene, were significantly protected from ischemia/reperfusion-induced acute kidney injury. The compound was most efficacious when administered within a well-determined time window of 2-4 hours post injury.
The study also proved that AKIi-5 has a favorable drug disposition (PK) profile, with short local exposure predominantly to the kidney-exhibiting rapid clearance of the drug post-administration. Quark's preclinical studies to date also indicate that AKIi-5 has a favorable safety profile, with a therapeutic index (toxic dose/effective dose) in rats greater than 250.
Elena Feinstein, M.D., Ph.D., the Company's Chief Scientific Officer, presented the results of the preclinical efficacy studies in a poster session at the Beyond Genome 2007 conference in San Francisco, CA. Quark's poster presentation was based on unpublished data.
The studies were performed in collaboration with Bruce A. Molitoris, M.D., Director of the Division of Nephrology and Professor of Medicine at Indiana University School of Medicine, and lead academic investigator in the Quark program.
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.